Landmark trial evaluates chemotherapy benefit in high-risk early-stage breast cancer
The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk, early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by ...
24 Sep 23:00 · Medical Xpress